A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.
We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.
An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.
The first results of the BrighTNess trial designed to evaluate the addition of veliparib (a PARP inhibitor) plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) have been published in the The Lancet Oncology.
A collaborative translational study that included data from six neoadjuvant GBG trials (GeparDuo, GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto) and investigated the role of tumour-infiltrating lymphocytes (TILs) as a prognostic factor in different subtypes of breast cancer after neoadjuvant therapy has been published in the The Lancet Oncology.